Article Image
IPFS News Link • Drug War

FDA Bars Generic Versions of Painkiller OxyContin

• Wall Street Journal
The FDA decision extends Purdue Pharma LP's patent protection of OxyContin for at least another year, if not much longer. The blockbuster pain drug racked up sales of $2.8 billion last year, according to IMS Health Inc. By blocking generic entrants, the FDA is signaling to the broader painkiller industry that it will reward companies that produce drugs with such safeguards.